IT Type
Antibody-based IT
Description
The immunotoxin includes (a) an anti-CD19 antibody lacking an Fc fragment, (b) a modified exotoxin A protein with both domains II and III, but lacking domain I, and (c) a peptide linker connecting the C-terminal end of the antibody to the N-terminal end of the modified exotoxin A protein. The linker is basically resistant to extracellular cleavage. The modified exotoxin A protein can be further modified to include a C-terminal KDEL sequence, which facilitates the transport of the protein to the endoplasmic reticulum of cells that have taken up the immunotoxin.
Indication
Refractory B-cell malignancies; B-cell Leukemia/Lymphoma
Classification
Immuntoxin; biobetter
Construction
4G7(scFv)-ETA
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 Molecule
Background
CD19 (CD19 Molecule) is a Protein Coding gene.Diseases associated with CD19 include Immunodeficiency, Common Variable, 3 and Common Variable Immunodeficiency. Among its related pathways are RET signaling and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. Gene Ontology (GO) annotations related to this gene include signal transducer activity, downstream of receptor.
Alternative Names
CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; B-Lymphocyte Antigen CD19; CVID3; B4;
Gene ID
Entrez Gene: 930
UniProt ID
UniProtKB: P15391
Antibody Clone
4G7
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Type
scFv
Antibody Indication
Refractory B-cell malignancies; B-cell Leukemia/Lymphoma
Toxic Moiety
Exfoliative toxin A (ETA)
Organism
Staphylococcus aureus
Family
Exfoliative toxin
Toxic MOA
The exfoliative toxins (ETs) also known as epidermolytic toxins, are serine proteases secreted by S. aureus that recognize and hydrolyze desmosome proteins. S. aureus ETs are serine proteases, which exhibit exquisite substrate specificity, and their mechanisms of action are extremely complex. However, the exact molecular mechanisms of ET‐causing epidermal blisters had long been unknown over the three decades.
The antibody portion mediated selective binding to target cells, while the toxin portion mediated translocation into the cytosol and subsequent cell killing.
Refractory B-cell malignancies; B-cell Leukemia/Lymphoma
